

## Bioservo - Edging closer to the inflection point

Redeye adjusts the short-term estimates downward due to a slightly more challenging business environment. The changes in estimates negatively affect our fair value range; however, we are still optimistic about the long-term prospects of both Ironhand and Carbonhand. We lower our Base case to SEK 16 (18) per share.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

**Bioservo - Edging closer to the inflection point**